---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-062184"
form_type: "8-K"
ticker: "RLMD"
cik: "0001553643"
company_name: "RELMADA THERAPEUTICS, INC."
filed_at: "2026-05-28T20:59:47+00:00"
generated_at: "2026-05-28T21:05:16.729164+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Relmada increases authorized common shares to 200M; stockholders approve 2021 Plan amendment

## Summary
- Authorized shares increased from 150M to 200M via charter amendment filed May 28, 2026.
- Annual meeting held May 27: 63.5% of eligible shares voted; directors Casamento and Traversa elected.
- Stockholders ratified CBIZ CPAs P.C. as auditor for FY 2026.
- 2021 Equity Incentive Plan amended to increase available shares by 3M to 18,052,942 total.
- Proposals 1-4 all approved; no material dissent on auditor or charter amendment.

## SEC filing metadata
- accession: 0001213900-26-062184
- form_type: 8-K
- ticker: RLMD
- cik: 0001553643
- company_name: RELMADA THERAPEUTICS, INC.
- filed_at: 2026-05-28T20:59:47+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.03, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1553643/000121390026062184/0001213900-26-062184-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1553643/000121390026062184/ea0292521-8k_relmada.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-062184
- JSON: https://secwatch.observer/filing/0001213900-26-062184.json
- Plain text: https://secwatch.observer/filing/0001213900-26-062184.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.